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Background. Epidemiological studies suggest that coﬀee consumption reduces the risk of cancer, but the molecular mechanisms
of its chemopreventive eﬀects remain unknown. Objective. To identify diﬀerentially expressed genes upon incubation of HT29
colon cancer cells with instant caﬀeinated coﬀee (ICC) or caﬀeic acid (CA) using whole-genome microarrays. Results. ICC
incubation of HT29 cells caused the overexpression of 57 genes and the underexpression of 161, while CA incubation induced
the overexpression of 12 genes and the underexpression of 32. Using Venn-Diagrams, we built a list of five overexpressed genes
and twelve underexpressed genes in common between the two experimental conditions. This list was used to generate a biological
association network in which STAT5B and ATF-2 appeared as highly interconnected nodes. STAT5B overexpression was confirmed
at themRNA and protein levels. For ATF-2, the changes inmRNA levels were confirmed for both ICC and CA, whereas the decrease
in protein levels was only observed in CA-treated cells. The levels of cyclin D1, a target gene for both STAT5B and ATF-2, were
downregulated by CA in colon cancer cells and by ICC and CA in breast cancer cells. Conclusions. Coﬀee polyphenols are able to
aﬀect cyclin D1 expression in cancer cells through the modulation of STAT5B and ATF-2.
1. Introduction
Polyphenols are the most abundant antioxidants in the diet.
Their main dietary sources are fruits and plant-derived bev-
erages such as fruit juices, tea, coﬀee, and red wine. Current
evidence strongly supports a contribution of polyphenols
to the prevention of cardiovascular diseases, cancers, and
osteoporosis suggesting a role of these antioxidants in
the prevention of neurodegenerative diseases and diabetes
mellitus [1].
It is well established that polyphenol ingestion results
in an increase of the plasma-antioxidant capacity. However,
there is still some uncertainties about their eﬃciency to
enhance the protection of cellular components, such as
lipids or DNA, against oxidative stress in humans [2].
Polyphenols and other antioxidants were thought to protect
cell constituents against oxidative damage by scavenging
free radicals. However, this concept now appears to be
an oversimplified view of their mode of action [3]. More
likely, cells respond to polyphenols mainly through direct
interactions with receptors or enzymes involved in signal
transduction, which may result in modification of the redox
status of the cell and may trigger a series of redox-dependent
reactions [4]. This could also apply to the anticarcinogenic
eﬀects of polyphenols, which properties may be explained by
many diﬀerent mechanisms.
Hydroxycinnamic acids are a major class of polyphenols
found in almost every plant [2]. The major representative
of hydroxycinnamic acids is caﬀeic acid, which occurs in
food mainly as an ester with quinic acid named chlorogenic
acid (5-caﬀeoylquinic acid). Coﬀee is a major source of
chlorogenic acid in the human diet; the daily intake in coﬀee
drinkers is 0.5–1 g whereas coﬀee abstainers will usually
ingest <100mg/day. Studies have shown that approximately
the 33% of ingested chlorogenic acid and the 95% of caﬀeic
acid are absorbed intestinally [5]. Thus, about two-thirds of
ingested chlorogenic acid reach the colon where it is probably
metabolized to caﬀeic acid [6].
Bioavailability data suggest that the biological eﬀects
of chlorogenic acid would become apparent after its
metabolism to caﬀeic acid, and hence the need of studying
the eﬀects of this acid. Chlorogenic acid and caﬀeic acid are
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antioxidants in vitro [7], and they might inhibit the forma-
tion of mutagenic and carcinogenic N-nitroso compounds
since they are inhibitors of the N-nitrosation reaction in
vivo [8]. Furthermore, chlorogenic acid can inhibit DNA
damage in vitro [9] as it inhibits lipid peroxidation-induced
DNA adduct formation [10] and suppresses reactive oxygen
species-mediated nuclear factor (NF-κB), activator protein-
1 (AP-1), and mitogen-activated protein kinase activation by
upregulating antioxidant enzymes [11]. These studies sug-
gested that coﬀee polyphenols are potent chemopreventive
agents.
Recent meta-analyses demonstrate inverse associations
between coﬀee intake and the risk of colon, liver, breast,
and endometrial cancer [12–15]. Moreover, in prospective
population-based cohort studies, the inverse association
between coﬀee consumption and risk of cancer has been
shown. The group of Naganuma [16] found that the con-
sumption of at least one cup of coﬀee per day was associated
with a 49% lower risk of upper gastrointestinal cancer in
a Japanese population, while Wilson and collaborators [17]
found that men who regularly drink coﬀee appeared to have
a lower risk of developing a lethal form of prostate cancer.
The lower risk was evident when consuming either regular
or decaﬀeinated coﬀee. It has been proposed that the inverse
association between coﬀee intake and colon cancer could be
explained, at least in part, by the presence of chlorogenic
acid in coﬀee [18]. Ganmaa et al. [19] observed a general
protective eﬀect of caﬀeine intake on breast cancer risk for
both ER subtypes, but the eﬀect was only found to be
significant for ER-positive breast cancers. In this study, the
association between caﬀeine and breast cancer was stronger
among postmenopausal women with estrogen-receptor and
progesterone-receptor-positive breast cancer than those with
estrogen-receptor and progesterone-receptor negative breast
cancer [19]. In another study, coﬀee drinking specifically
reduced the risk of developing ER-negative breast cancer but
not ER-positive breast cancer [20].
Although there is enough evidence from epidemiological
data supporting that coﬀee seems to reduce the risk of
certain cancers, the molecular mechanisms underlying the
chemopreventive eﬀects of coﬀee remain unknown. For this
reason, the aim of our study was to determine the eﬀect at the
molecular level of coﬀee polyphenols at low concentrations
equivalent to one cup of coﬀee, using as a model a human
colon cancer cell line HT29 in a nutrigenomic approach.
Furthermore, the eﬀect of coﬀee polyphenols was also
evaluated in breast cancer cells.
2. Materials and Methods
2.1. Materials and Chemicals. Cells were incubated with
Instant Caﬀeinated Coﬀee (ICC) (regular lyophilized instant
coﬀee) and Caﬀeic acid (CA, Sigma). Compounds were
dissolved either in DMSO (CA), or sterile water (ICC), and
stored at −20◦C.
2.2. Cell Culture. Colon adenocarcinoma HT29 and breast
cancer MCF-7 cell lines were routinely grown in Ham’s
F12 medium supplemented with 7% fetal bovine serum
(FBS, both from Gibco) at 37◦C in a 5% CO2 humidified
atmosphere in 10 cm dish, or in 33mm plate.
Cells were incubated with ICC or CA at concentrations
equivalent to one cup of coﬀee. The concentrations used
in cell incubations, 7 μg/mL in H2O mQ for ICC and
1.68 μg/mL in DMSO for CA, respectively, took into account
the amount of these compounds in one cup of coﬀee and
their distribution in a regular human body with 75% water
content. These concentrations did not cause any cytotoxic
eﬀect in the cell incubations as determined by the MTT assay
[21].
2.3. Microarrays. Gene expression was analyzed by hybrid-
ization to The GeneChip Human Genome U133A plus 2.0
microarrays from Aﬀymetrix, containing 47,000 transcripts
and variants. HT29 cells were incubated with ICC and CA for
24 h. Total RNA was prepared from triplicate samples using
Speedtools Total RNA Extraction Kit (Biotools) following
the recommendations of the manufacturer. RNA quality
was tested by 2100 Bioanalyzer Eukaryote Total RNA Nano
Series II (Agilent Technologies). Labeling, hybridization, and
detection were carried out following the manufacturer’s
specifications at the IDIBAPS Genomic Service (Hospital
Clı´nic, Barcelona).
2.4. Microarray Data Analyses. Quantification was carried
out with GeneSpring GX v.11.5.1 software (Agilent Tech-
nologies), which allows multifilter comparisons using data
from diﬀerent experiments to perform the normalization,
generation of lists, and the functional classification of the
diﬀerentially expressed genes. The input data was subjected
to preprocess baseline transformation using the Robust
Multiarray Average summarization algorithm using the
median of control samples. After grouping the triplicate of
each experimental condition, list of diﬀerentially expressed
genes could be generated by using volcano plot analysis.
The expression of each gene is reported as the ratio of
the value obtained after each condition relative to control
condition after normalization and statistical analysis of the
data. The corrected P value cutoﬀ applied was of <0.05;
then the output of this statistical analysis was filtered by
fold expression, selecting specifically those genes that had a
diﬀerential expression of at least 1.3-fold. Gene classification
was established by the Gene Ontology database.
2.5. Common Genes between ICC and CA Treatments. Com-
mon genes were selected from the lists of diﬀerentially
expressed genes for each treatment using Venn-Diagrams.
The newly generated list contained both over and underex-
pressed genes.
2.6. Generation of Biological Association Networks. BANs
were constructed with the aid of the Pathway Analysis within
the GeneSpring v.11.5.1 (Agilent) as described in Selga et al.
[22] with the list of common genes diﬀerentially expressed
in both treatments. A filtered screening was processed by
the program between our data and bibliographic interaction
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databases up to a total of 100 related genes. Network associ-
ations were confirmed in the literature.
2.7. RT Real-Time PCR. Total RNA was extracted from
HT29 cells using Ultraspec (Biotex) in accordance with the
manufacturer’s instructions.
Complementary DNA was synthesized as described in
Selga et al. [23] and the cDNA product was used for ampli-
fication by real time PCR. STAT5B and ATF-2 mRNA levels
were determined in an ABI Prism 7000 Sequence Detection
System (Applied Biosystems) using 3 μL of the cDNA
reaction and the assays-on-demand Hs00560035 m1 for
STAT5B, Hs00153179 ml for ATF-2, and Hs00356991 m1
for APRT (all from Applied Biosystems). APRT mRNA
was used as an endogenous control. The reaction was
performed following the manufacturers recommendations.
Fold changes in gene expression were calculated using the
standard ΔΔCt method.
2.8. Western Blot. Whole extracts were obtained from 2.5 ×
106 control or treated cells according to Selga et al. [23].
Five μL of the extract was used to determine protein
concentration by the Bradford assay (Bio-Rad). The extracts
were frozen in liquid N2 and stored at −80◦C. Total extracts
(50 μg) were resolved on SDS-polyacrylamide gels and
transferred to PVDF membranes (Immobilon P, Millipore)
using a semidry electroblotter.
The SNAP i.d. protein detection system technology
(Millipore) was used to probe the membranes. This system
applies vacuum through the membrane to actively drive
reagents to protein locations, unlike the traditional technique
of diﬀusion over the membrane as a reagent transport.
Table 1 compiles the antibodies used in the diﬀerent determ-
inations.
Signals were detected by secondary horseradish peroxid-
ase-conjugated antibody, either anti-rabbit (1 : 5000 or
1 : 10000 dilution; Dako) or anti-mouse (1 : 2500 dilution,
Amersham NIF 824) and enhanced chemiluminescence
using the ECL method, as recommended by the manufac-
turer (Amersham). Chemiluminescence was detected with
ImageQuant LAS 4000 Mini technology (GE Healthcare).
2.9. Statistical Methods. For the RT-PCR and Western blot
analyses, values are expressed as the mean ± SE of three
diﬀerent experiments. Data were evaluated by unpaired
Student’s t test, and analyses were performed using the PASW
Statistics v. 18.0.0. software.
3. Results
3.1. Eﬀect of ICC and CA Incubations in HT29 Gene Expres-
sion. The expression profile of over 47,000 transcripts and
variants included in the microarray HG U133 plus 2.0
from Aﬀymetrix was compared between HT29 control cells
and cells incubated with either CA or ICC, at nontoxic
concentrations for 24 h. GeneSpring GX software v.11.5.1
was used to analyze the results. A list of diﬀerentially
expressed genes by 1.3-fold with a P value cutoﬀ of <0.05 was
generated as described in Methods. When HT29 cells were
incubated with ICC, 57 genes were overexpressed whereas
161 genes were underexpressed. Among the overexpressed
genes, 24% belonged to the Transcription factors category
and 19% to Cell cycle or to Biosynthetic processes. Within
the underexpressed genes, the category corresponding to cell
cycle was the most aﬀected (53% of the genes) followed
by Transcription factors (19%) and Biosynthetic processes
(12%). Upon incubation with CA, 12 genes were overex-
pressed whereas 32 genes were underexpressed. Among the
overexpressed genes, 33% belonged to the Transcription
factors category, 25% to Cell cycle, and 16,7% to Biosynthetic
processes or immune response. Within the underexpressed
genes, again the category corresponding to Cell cycle was
the most aﬀected (30% of the genes) followed by Biosyn-
thetic processes (15%) and Transcription factors (12%).
The lists of diﬀerentially expressed genes are presented as
Tables 2, 3, 4, and 5. The data presented in this work
have been deposited in the Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible
through GEO series accession number [GSM867162].
3.2. Generation of Biological Association Networks. A Biolog-
ical Association Network (BAN) was constructed using the
Pathway Analysis within GeneSpring v.11.5.1 as described
in Methods using as the starting list the common genes
diﬀerentially expressed upon incubation with CA and ICC.
This list included five overexpressed genes and twelve under-
expressed genes (Table 6). In the generated network, signal
transducer and activator of transcription 5B (STAT5B) and
activating transcription factor 2 (ATF-2) appeared as highly
interconnected nodes (Figure 1). These twomain nodes were
selected for further validations. STAT5B was overexpressed
with respect to the control by 23.8% in cells treated with
ICC and by 33.4% in cells treated with CA, whereas ATF-
2 was found underexpressed in HT29 incubated with ICC
(32.5% decrease compared to the control) and with CA (26%
decrease).
3.3. Validation of STAT5B and ATF-2 Changes at the mRNA
and Protein Levels. STAT5B overexpression in HT29 cells
upon incubation with CA and ICC was confirmed at
the mRNA (1.16- and 1.3-fold compared to the control,
respectively) and protein levels (1.5- and 1.2-fold compared
to the control, respectively) (Figures 2(a) and 2(c)). In the
case of ATF-2, the changes in mRNA levels were confirmed
for both CA and ICC (0.88- and 0.86-fold compared to the
control, respectively), whereas the decrease in protein levels
was only observed in CA-treated cells (0.62-fold compared to
the control) (Figures 2(b) and 2(d)).
3.4. Expression of Cyclin D1 upon Incubation with ICC and
CA. Cyclin D1 is overexpressed at the mRNA and protein
level in over 50% of the breast cancers either in the presence
or absence of gene amplification, and it is one of the most
commonly overexpressed proteins in breast cancer [24, 25].
Cyclin D1 transcription is regulated by STAT5 [26–29] and
ATF-2 [30–32].
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Figure 1: Biological association network (BAN) of diﬀerentially expressed genes in common between CA and ICC. The list of common
genes between both treatments was used to construct a BAN with the Pathway Analysis software within GeneSpring v.11.5.1. An expanded
network was constructed by setting an advanced filter that included the categories of binding, expression, metabolism, promoter binding,
protein modification, and regulation. Only proteins are represented. The BAN shows the node genes STAT5B and ATF-2 that were further
studied.
Table 1
Antibody Molecular weight (KDa) Dilution used Supplier
STAT5B 95 1: 200 sc-835, Santa Cruz Biotechnology Inc.
ATF-2 72 1: 200 sc-6233, Santa Cruz Biotechnology Inc.
Cyclin D1 38 1: 200 sc-8396, Santa Cruz Biotechnology Inc.
β-actin 42 1: 200 A2066, Sigma
Tubulin 60 1: 100 CP06, Calbiochem
We analyzed the levels of cyclin D1 by western blot in
MCF-7 and HT29 cells upon incubation with ICC and CA.
As shown in Figure 3(a), incubation of MCF-7 cells with
either CA and ICC led to a drastic decrease in the levels of
cyclin D1 protein, together with an increase in the levels of
STAT5B, but not to a decrease in the levels of ATF-2. In HT29
cells, incubation with CA did not aﬀect cyclin D1 levels,
whereas the presence of ICC led to an increase in cyclin D1
levels 3 (b).
4. Discussion
In this work we analyzed the gene expression profile of
human cancer cells treated with either ICC or CA. Caﬀeic
acid was chosen since it is the main representative of
hydroxycinnamic acids. Using microarrays we identified the
diﬀerential expression of specific genes involved in several
biological pathways. The changes in mRNA expression of
two outlier genes, STAT5B and ATF-2, observed in the
microarrays were confirmed by RT real-time PCR, and the
changes in protein levels were also analyzed by Western blot.
The selection of STAT5B and ATF-2 was made according
to the results obtained in the construction of a biological
association network. Finally, the modulation of cyclin D1,
a target of STAT5B and ATF-2 transcription factors, upon
incubation with coﬀee polyphenols was also established.
We show that ICC and the amount of CA of one cup
of coﬀee are able to induce STAT5B mRNA and protein
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Figure 2: Quantitation of mRNA and protein levels for STAT5B and ATF-2 in HT29 cells. The mRNA levels of STAT5B (a) and ATF-2 (b)
were determined in control HT29 cells (empty bars) and cells treated with caﬀeic acid (CA, filled bars) and instant caﬀeinated coﬀee (ICC,
grey bars) by RT real-time PCR as described in Methods. Results are expressed in fold changes compared to the control and are the mean ±
SE of 3 diﬀerent experiments. ∗P < 0.05 compared with the corresponding control. The protein levels of STAT5B (c) and ATF-2 (d) were
determined in control HT29 cells (empty bars) and cells treated with caﬀeic acid (CA, filled bars) and instant caﬀeinated coﬀee (ICC, grey
bars) byWestern blot. Blots were reprobed with an antibody against β-actin or tubulin to normalize the results. Results represent the mean ±
SE of 3 diﬀerent experiments. ∗P < 0.05 and ∗∗P < 0.01 compared with the corresponding control.
6 Oxidative Medicine and Cellular Longevity
Table 2: List of overexpressed genes in HT29 cells upon incubation with instant caﬀeinated coﬀee.
Gene symbol Gene title P value FC absolute Regulation
CALM3 Calmodulin 3 (phosphorylase kinase, delta) 0.016 1.3 Up
CDC42EP1 CDC42 eﬀector protein (Rho GTPase binding) 1 0.027 1.3 Up
FOXN3 Forkhead box N3 0.022 1.3 Up
KIR2DL1 Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1 0.023 1.3 Up
ORAI2 ORAI calcium release-activated calcium modulator 2 0.011 1.3 Up
RAPGEF1 Rap guanine nucleotide exchange factor (GEF) 1 0.022 1.3 Up
STH Saitohin 0.031 1.3 Up
SLC39A3 Solute carrier family 39 (zinc transporter), member 3 0.028 1.3 Up
ZNF397OS Zinc finger protein 397 opposite strand 0.024 1.3 Up
ZP4 Zona pellucida glycoprotein 4 0.046 1.3 Up
FGFRL1 Fibroblast growth factor receptor-like 1 0.035 1.31 Up
ITGA9 Integrin, alpha 9 0.002 1.31 Up
IRAK1 Interleukin-1 receptor-associated kinase 1 0.038 1.31 Up
OBSL1 Obscurin-like 1 0.008 1.31 Up
RPS17L4 Ribosomal protein S17-like 4 0.026 1.31 Up
STAT5B Signal transducer and activator of transcription 5B 0.007 1.31 Up
TRABD TraB domain containing 0.043 1.31 Up
MYO9B Myosin IXB 0.041 1.32 Up
NME7 Nonmetastatic cells 7, protein expressed in (nucleoside-diphosphate kinase) 0.037 1.32 Up
RPS6KA4 Ribosomal protein S6 kinase, 90 kDa, polypeptide 4 0.014 1.32 Up
SIRPA Signal-regulatory protein alpha 0.019 1.32 Up
TBX20 T-box 20 0.035 1.32 Up
TCF20 Transcription factor 20 (AR1) 0.022 1.32 Up
ALDH3B1 Aldehyde dehydrogenase 3 family, member B1 0.005 1.33 Up
BGN Biglycan 0.029 1.33 Up
GNB4 Guanine nucleotide binding-protein (G protein), b-polypeptide 4 0.044 1.33 Up
IFNA17 Interferon, alpha 17 0.026 1.33 Up
KY Kyphoscoliosis peptidase 0.013 1.33 Up
SCARF1 Scavenger receptor class F, member 1 0.025 1.33 Up
SERPINB8 Serpin peptidase inhibitor, clade B (ovalbumin), member 8 0.01 1.33 Up
FST Follistatin 0.025 1.34 Up
MOGAT1 Monoacylglycerol O-acyltransferase 1 0.009 1.34 Up
PPARGC1A Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 0.015 1.34 Up
SUCLG2 Succinate-CoA ligase, GDP-forming, beta subunit 0.011 1.34 Up
SULT1B1 Sulfotransferase family, cytosolic, 1B, member 1 0.018 1.34 Up
TBX10 T-box 10 0.011 1.34 Up
ZNF503 Zinc finger protein 503 0.022 1.34 Up
HBA1 Hemoglobin, alpha 1 0.04 1.35 Up
MEPE Matrix, extracellular phosphoglycoprotein with ASARM motif 0.001 1.35 Up
PPP1CB Protein phosphatase 1, catalytic subunit, beta isoform 0.03 1.35 Up
ARV1 ARV1 homolog (S. cerevisiae) 0.011 1.36 Up
BCL3 B-cell CLL/lymphoma 3 0.034 1.36 Up
CTRC Chymotrypsin C (caldecrin) 0.045 1.36 Up
EPOR Erythropoietin receptor 0.008 1.37 Up
HMGA1 High-mobility group AT-hook 1 0.039 1.37 Up
IL19 Interleukin 19 0.018 1.38 Up
ABCC12 ATP-binding cassette, subfamily C (CFTR/MRP), member 12 6.00E-04 1.39 Up
RAI1 Retinoic acid induced 1 0.017 1.39 Up
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Table 2: Continued.
Gene symbol Gene title P value FC absolute Regulation
KLF5 Kruppel-like factor 5 (intestinal) 0.028 1.4 Up
CBWD1 COBW domain containing 1 0.044 1.41 Up
ASAH3 N-acylsphingosine amidohydrolase (alkaline ceramidase) 3 0.039 1.43 Up
ABHD14B Abhydrolase domain containing 14B 0.03 1.45 Up
TLN1 Talin 1 0.049 1.45 Up
ARHGAP23 Rho GTPase-activating protein 23 0.024 1.65 Up
HINT3 Histidine triad nucleotide binding protein 3 0.002 1.77 Up
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 0.034 1.83 Up
CALR Calreticulin 0.007 1.93 Up
The table shows the list of overexpressed genes by 1.3-fold with a P value < 0.05 obtained in cells treated with instant caﬀeinated coﬀee and includes the gene
symbol for all genes, and their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group
and the type of regulation (up: upregulation).
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Figure 3: Expression of cyclin D1 upon incubation with ICC and CA in HT29 and MCF-7 cells. (a) Quantitation of STAT5b (empty bars),
ATF-2 (filled bars), and cyclin D1 (grey bars) protein levels in MCF-7 cells. The protein levels were determined in control MCF-7 cells
(CNT) and cells treated with caﬀeic acid (CA) and instant coﬀee (ICC) by Western blot. Blots were reprobed with an antibody against
β-actin to normalize the results. Results represent the mean ± SE of 3 diﬀerent experiments. ∗P < 0.05 and ∗∗∗P < 0.001 compared with
the corresponding control. (b) Quantitation of STAT5b (empty bars), ATF-2 (filled bars), and cyclin D1 (grey bars) protein levels in HT29
cells. The protein levels were determined in control HT29 cells (CNT) and cells treated with caﬀeic acid (CA) and instant coﬀee (ICC) by
Western blot. Blots were reprobed with an antibody against β-actin to normalize the results. Results represent the mean ± SE of 3 diﬀerent
experiments.∗P < 0.05 and ∗∗P < 0.01 compared with the corresponding control.
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Table 3: List of underexpressed genes in HT29 cells upon incubation with instant coﬀee.
Gene symbol Gene title P value FC absolute Regulation
ACBD5 Acyl-coenzyme A binding domain containing 5 0.017 1.3 Down
CXADR Coxsackie virus and adenovirus receptor 0.015 1.3 Down
FANCD2 Fanconi anemia, complementation group D2 0.047 1.3 Down
FRYL FRY-like 0.039 1.3 Down
NUB1 Negative regulator of ubiquitin-like proteins 1 0.029 1.3 Down
PBRM1 Polybromo 1 0.004 1.3 Down
PRKACB Protein kinase, cAMP-dependent, catalytic, beta 0.033 1.3 Down
RIF1 RAP1 interacting factor homolog (yeast) 0.012 1.3 Down
SLC39A6 Solute carrier family 39 (zinc transporter), member 6 0.022 1.3 Down
TMEM170 Transmembrane protein 170 0.032 1.3 Down
WDR26 WD repeat domain 26 0.028 1.3 Down
RNGTT RNA guanylyltransferase and 5′-phosphatase 0.04 1.3 Down
CTDSPL2 CTD small phosphatase like 2 0.03 1.3 Down
ZC3H11A Zinc finger CCCH-type containing 11A 0.014 1.3 Down
TMOD3 Tropomodulin 3 (ubiquitous) 0.0171 1.3 Down
CPD Carboxypeptidase D 0.002 1.31 Down
CBL Cas-Br-M ecotropic retroviral transforming sequence 0.008 1.31 Down
CDC42SE2 CDC42 small eﬀector 2 0.022 1.31 Down
CLN5 Ceroid-lipofuscinosis, neuronal 5 0.001 1.31 Down
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 0.027 1.31 Down
FGFR1OP2 FGFR1 oncogene partner 2 0.049 1.31 Down
LRRFIP1 Leucine-rich repeat (in FLII) interacting protein 1 0.026 1.31 Down
PDCD4 Programmed cell death 4 0.005 1.31 Down
REPS2 RALBP1-associated Eps domain containing 2 0.046 1.31 Down
SLC7A6 Solute carrier family 7, member 6 0.002 1.31 Down
TFRC Transferrin receptor (p90, CD71) 0.038 1.31 Down
TMEM19 Transmembrane protein 19 0.024 1.31 Down
AGPS Alkylglycerone phosphate synthase 0.001 1.31 Down
SLC4A7 Solute carrier family 4, member 7 0.028 1.31 Down
SPTAN1 Spectrin, alpha, nonerythrocytic 1 (alpha-fodrin) 0.02 1.31 Down
GPD2 Glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 0.033 1.31 Down
BICD1 Bicaudal D homolog 1 (Drosophila) 0.008 1.31 Down
FBXW11 F-box and WD repeat domain containing 11 0.025 1.31 Down
BCLAF1 BCL2-associated transcription factor 1 0.025 1.32 Down
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 0.011 1.32 Down
CLK4 CDC-like kinase 4 0.049 1.32 Down
PTAR1 Protein prenyltransferase alpha subunit repeat containing 1 0.027 1.32 Down
SMEK2 SMEK homolog 2, suppressor of mek1 (Dictyostelium) 0.012 1.32 Down
CEPT1 Choline/ethanolamine phosphotransferase 1 0.038 1.32 Down
SAR1A SAR1 gene homolog A (S. cerevisiae) 0.033 1.32 Down
PDGFC Platelet-derived growth factor C 0.02 1.32 Down
NFAT5 Nuclear factor of activated T-cells 5, tonicity responsive 0.045 1.32 Down
FRS2 Fibroblast growth factor receptor substrate 2 0.03 1.32 Down
BMS1P5 BMS1 pseudogene 5 0.036 1.33 Down
GLS Glutaminase 5.00E-04 1.33 Down
LMAN1 Lectin, mannose binding, 1 7.00E-04 1.33 Down
ARHGAP18 Rho GTPase-activating protein 18 8.00E-04 1.33 Down
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Table 3: Continued.
Gene symbol Gene title P value FC absolute Regulation
ARHGAP5 Rho GTPase-activating protein 5 0.006 1.33 Down
CCNE2 Cyclin E2 0.036 1.33 Down
SPCS3 Signal peptidase complex subunit 3 homolog (S. cerevisiae) 0.008 1.33 Down
NCOA2 Nuclear receptor coactivator 2 0.005 1.33 Down
SRPRB Signal recognition particle receptor, B subunit 0.018 1.33 Down
TLK1 Tousled-like kinase 1 0.04 1.33 Down
NCOA3 Nuclear receptor coactivator 3 0.048 1.33 Down
STRN3 Striatin, calmodulin-binding protein 3 2.00E-04 1.33 Down
AP1G1 Adaptor-related protein complex 1, gamma 1 subunit 0.004 1.34 Down
B3GALNT2 Beta-1,3-N-acetylgalactosaminyltransferase 2 0.034 1.34 Down
PPHLN1 Periphilin 1 2.00E-04 1.34 Down
SNX13 Sorting nexin 13 0.001 1.34 Down
TMED2 Transmembrane emp24 domain-traﬃcking protein 2 0.041 1.34 Down
BRWD1 Bromodomain and WD repeat domain containing 1 0.011 1.34 Down
HLA-B Major histocompatibility complex, class I, B 0.028 1.34 Down
CHP Calcium-binding protein P22 0.002 1.34 Down
MTMR9 Myotubularin-related protein 9 0.026 1.34 Down
DCUN1D4 DCN1, defective in cullin neddylation 1, domain containing 4 0.031 1.34 Down
ARL6IP2 ADP-ribosylation factor-like 6 interacting protein 2 0.02 1.35 Down
GLIS3 GLIS family zinc finger 3 0.01 1.35 Down
LARP4 La ribonucleoprotein domain family, member 4 0.019 1.35 Down
PTPLB Protein tyrosine phosphatase-like member b 0.036 1.35 Down
TRAM1 Translocation-associated membrane protein 1 0.002 1.35 Down
TMEM64 Transmembrane protein 64 0.001 1.35 Down
CBFB Core-binding factor, beta subunit 0.005 1.35 Down
SELT Selenoprotein T 0.002 1.35 Down
PEX13 Peroxisome biogenesis factor 13 0.011 1.35 Down
TNKS2 TRF1-interacting ankyrin-related ADP-ribose polymerase 2 0.034 1.35 Down
TMPO Thymopoietin 0.001 1.35 Down
LIN7C Lin-7 homolog C (C. elegans) 0.007 1.35 Down
MTA2 Metastasis-associated 1 family, member 2 0.013 1.36 Down
TMEM168 Transmembrane protein 168 0.035 1.36 Down
CREBZF CREB/ATF bZIP transcription factor 0.016 1.36 Down
OSTF1 Osteoclast-stimulating factor 1 0.002 1.36 Down
WDR57 WD repeat domain 57 (U5 snRNP specific) 0.001 1.36 Down
GLT25D1 Glycosyltransferase 25 domain containing 1 0.008 1.36 Down
NAPG N-ethylmaleimide-sensitive factor attachment protein, gamma 0.015 1.36 Down
CCDC126 Coiled-coil domain containing 126 0.039 1.37 Down
LASS6 LAG1 homolog, ceramide synthase 6 0.005 1.37 Down
MYSM1 Myb-like, SWIRM and MPN domains 1 0.021 1.37 Down
CYP51A1 Cytochrome P450, family 51, subfamily A, polypeptide 1 0.007 1.37 Down
PDE4DIP Phosphodiesterase 4D interacting protein (myomegalin) 0.024 1.37 Down
SAP30L SAP30-like 0.012 1.37 Down
PTPRJ Protein tyrosine phosphatase, receptor type, J 0.011 1.37 Down
PGGT1B Protein geranylgeranyltransferase type I, beta subunit 9.00E-04 1.37 Down
ASPH Aspartate beta-hydroxylase 0.011 1.37 Down
SEMA3C Sema domain, (semaphorin) 3C 0.036 1.38 Down
WDR76 WD repeat domain 76 0.016 1.38 Down
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Table 3: Continued.
Gene symbol Gene title P value FC absolute Regulation
ATP13A3 ATPase-type 13A3 0.002 1.38 Down
LMBR1 Limb region 1 homolog (mouse) 0.014 1.38 Down
GLUD1 Glutamate dehydrogenase 1 0.001 1.39 Down
GSTCD Glutathione S-transferase, C-terminal domain containing 0.029 1.39 Down
SPTLC1 Serine palmitoyltransferase, subunit 1 0.02 1.39 Down
U2AF1 U2 small nuclear RNA auxiliary factor 1 9.00E-04 1.39 Down
UHMK1 U2AF homology motif (UHM) kinase 1 0.007 1.39 Down
ARGLU1 Arginine and glutamate-rich 1 6.00E-04 1.39 Down
ANKRD12 Ankyrin repeat domain 12 0.03 1.39 Down
PPP3R1 Protein phosphatase 3, regulatory subunit B, alpha isoform 0.023 1.39 Down
XRN1 5′-3′ exoribonuclease 1 0.019 1.4 Down
CLSPN Claspin homolog (Xenopus laevis) 0.013 1.4 Down
CXADRP1 Coxsackie virus and adenovirus receptor pseudogene 1 0.034 1.4 Down
G3BP1 GTPase-activating protein- (SH3 domain) binding protein 1 0.002 1.4 Down
TMEM30A Transmembrane protein 30A 0.01 1.4 Down
CLCN3 Chloride channel 3 0.035 1.41 Down
STK4 Serine/threonine kinase 4 0.039 1.41 Down
ZNF644 Zinc finger protein 644 0.02 1.41 Down
TCP11L1 T-complex 11 (mouse)-like 1 0.014 1.41 Down
SFRS6 Splicing factor, arginine/serine-rich 6 0.031 1.41 Down
NPL N-acetylneuraminate pyruvate lyase 0.006 1.41 Down
G3BP2 GTPase-activating protein- (SH3 domain) binding protein 2 0.001 1.42 Down
HNRNPU Heterogeneous nuclear ribonucleoprotein U 0.01 1.42 Down
TBL1XR1 Transducin (beta)-like 1 X-linked receptor 1 0.001 1.42 Down
PHTF2 Putative homeodomain transcription factor 2 0.002 1.42 Down
ADAM10 ADAM metallopeptidase domain 10 0.011 1.43 Down
ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 0.01 1.43 Down
MALAT1 Metastasis-associated lung adenocarcinoma transcript 1 0.04 1.43 Down
SCARB2 Scavenger receptor class B, member 2 0.001 1.43 Down
CANX Calnexin 0.043 1.43 Down
CASP2 Caspase 2, apoptosis-related cysteine peptidase 0.033 1.43 Down
TRPS1 Trichorhinophalangeal syndrome I 0.005 1.44 Down
ZFX Zinc finger protein, X-linked 0.033 1.44 Down
SGPL1 Sphingosine-1-phosphate lyase 1 0.04 1.44 Down
PTPN11 Protein tyrosine phosphatase, nonreceptor type 11 0.045 1.44 Down
SFRS11 Splicing factor, arginine/serine-rich 11 0.045 1.45 Down
B3GNT5 Beta-1,3-N-acetylglucosaminyltransferase 5 0.021 1.45 Down
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 0.019 1.45 Down
SNHG4 Small nucleolar RNA host gene (nonprotein coding) 4 0.004 1.46 Down
PARD6B Par-6 partitioning defective 6 homolog beta (C. elegans) 0.04 1.46 Down
ROD1 ROD1 regulator of diﬀerentiation 1 (S. pombe) 0.001 1.46 Down
SPTBN1 Spectrin, beta, nonerythrocytic 1 0.02 1.48 Down
TXNDC1 Thioredoxin domain containing 1 0.013 1.48 Down
ATF2 Activating transcription factor 2 0.005 1.48 Down
RDX Radixin 0.043 1.48 Down
SCAMP1 Secretory carrier membrane protein 1 0.009 1.48 Down
PTAR1 Protein prenyltransferase alpha subunit repeat containing 1 0.018 1.49 Down
RC3H2 Ring finger and CCCH-type zinc finger domains 2 0.0037 1.49 Down
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Table 3: Continued.
Gene symbol Gene title P value FC absolute Regulation
ADAM17 ADAM metallopeptidase domain 17 0.007 1.49 Down
FAM76B Family with sequence similarity 76, member B 0.014 1.5 Down
ITGB8 Integrin, beta 8 1.00E-04 1.5 Down
TRIM23 Tripartite motif-containing 23 0.005 1.5 Down
CASC5 Cancer susceptibility candidate 5 0.019 1.52 Down
SLC16A1 Solute carrier family 16, member 1 0.002 1.52 Down
FNBP1 Formin-binding protein 1 0.037 1.53 Down
PRKAR1A Protein kinase, cAMP-dependent, regulatory, type I, alpha 9.00E-04 1.53 Down
B4GALT1 Beta 1,4-galactosyltransferase, polypeptide 1 0.035 1.55 Down
MDM4 Mdm4 p53-binding protein homolog (mouse) 0.011 1.58 Down
FGD4 FYVE, RhoGEF, and PH domain containing 4 0.001 1.59 Down
UBA6 Ubiquitin-like modifier activating enzyme 6 8.00E-04 1.62 Down
ZDHHC21 Zinc finger, DHHC-type containing 21 0.036 1.64 Down
REEP3 Receptor accessory protein 3 7.00E-04 1.65 Down
SSR3 Signal sequence receptor, gamma 0.014 1.65 Down
ZDHHC20 Zinc finger, DHHC-type containing 20 0.003 1.66 Down
EIF2S3 Eukaryotic translation initiation factor 2, subunit 3 gamma 0.001 1.7 Down
HNRNPH1 Heterogeneous nuclear ribonucleoprotein H1 0.011 1.79 Down
ATL3 Atlastin 3 0.001 2.02 Down
The table shows the list of underexpressed genes by 1.3-fold with a P value < 0.05 obtained in cells treated with instant caﬀeinated coﬀee and includes the gene
symbol for all genes, and their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group
and the type of regulation (down: downregulation).
Table 4: List of overexpressed genes in HT29 cells upon incubation with caﬀeic acid.
Gene symbol Gene title P value FC absolute Regulation
SULT1B1 Sulfotransferase family, cytosolic, 1B, member 1 0.02 1.3 Up
BCL6B B-cell CLL/lymphoma 6, member B (zinc finger protein) 3.00E-04 1.3 Up
KCNJ5 Potassium inwardly-rectifying channel, subfamily J, member 5 0.01 1.31 Up
EPOR Erythropoietin receptor 0.02 1.32 Up
DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 0.049 1.33 Up
STAT5B Signal transducer and activator of transcription 5B 0.012 1.33 Up
FST Follistatin 0.021 1.37 Up
CD84 CD84 molecule 0.033 1.37 Up
THRA Thyroid hormone receptor, alpha 0.017 1.37 Up
MAPK8IP3 Mitogen-activated protein kinase 8 interacting protein 3 0.028 1.4 Up
SIAE Sialic acid acetylesterase 0.01 2.42 Up
HINT3 Histidine triad nucleotide-binding protein 3 0.033 2.6 Up
The table shows the list of overexpressed genes by 1.3-fold with a P value < 0.05 obtained in cells treated with caﬀeic acid and includes the gene symbol for
all genes, their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group and the type of
regulation (up: upregulation).
levels in HT29 cells. STAT5 was originally described as a
prolactin-induced mammary gland factor [33]. The cloning
of two closely related STAT5 cDNAs, from both mouse and
human cDNA libraries, showed two distinct genes, STAT5A
and STAT5B that encoded two STAT5 proteins [34–37].
In addition to prolactin, STAT5 proteins are activated by
a wide variety of cytokines and growth factors, including
IL-2, IL-3, IL-5, IL-7, IL-9, IL-15, granulocyte-macrophage
colony-stimulating factor, erythropoietin, growth hormone,
thrombopoietin, epidermal growth factor, and platelet-
derived growth factor. The key function of STAT5B is to
mediate the eﬀects of growth hormone [38, 39]. Modulation
of STAT5 levels or transcriptional activity has already been
described in cells treated with natural compounds such as
nobiletin, a citrus flavonoid [40], thea flavins [41], and
silibinin, a natural polyphenolic flavonoid which is a major
bioactive component of silymarin isolated from Silybum
marianum [42]. Furthermore, it has been reported that
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Table 5: List of underexpressed genes in HT29 cells upon incubation with caﬀeic acid.
Gene symbol Gene title P value FC absolute Regulation
MFSD7 Major facilitator superfamily domain containing 7 1.00E-04 1.3 Down
MSI2 Musashi homolog 2 (Drosophila) 0.027 1.3 Down
CDA Cytidine deaminase 2.00E-04 1.31 Down
DEFB1 Defensin, beta 1 0.026 1.31 Down
PIP5K1A Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha 0.027 1.31 Down
ZDHHC20 Zinc finger, DHHC-type containing 20 0.005 1.31 Down
ZDHHC21 Zinc finger, DHHC-type containing 21 0.016 1.31 Down
SLC4A7 Solute carrier family 4, member 7 0.0249 1.32 Down
CEACAM1 Carcinoembryonic antigen-related cell adhesionmolecule 1 0.0459 1.32 Down
PDZRN3 PDZ domain containing RING finger 3 0.002 1.32 Down
WDR62 WD repeat domain 62 0.005 1.32 Down
FAM76B Family with sequence similarity 76, member B 0.036 1.32 Down
TCF21 Transcription factor 21 0.029 1.33 Down
TBL1XR1 Transducin (beta)-like 1 X-linked receptor 1 6.00E-04 1.33 Down
CLK4 CDC-like kinase 4 0.021 1.33 Down
CYP2A13 Cytochrome P450, family 2, subfamily A, polypeptide 13 0.009 1.34 Down
CXCR4 Chemokine (C-X-C motif) receptor 4 0.0488 1.34 Down
ATF2 Activating transcription factor 2 0.0158 1.35 Down
PDE10A Phosphodiesterase 10A 0.03 1.35 Down
METT10D Methyltransferase 10 domain containing 0.003 1.35 Down
PRMT2 Protein arginine methyltransferase 2 7.00E-04 1.36 Down
GLS Glutaminase 5.70E-04 1.37 Down
SLC38A5 Solute carrier family 38, member 5 0.043 1.37 Down
TINAG Tubulointerstitial nephritis antigen 0.043 1.38 Down
AQP1 Aquaporin 1 (Colton blood group) 0.0221 1.4 Down
JMJD6 Jumonji domain containing 6 0.004 1.4 Down
SAP30L SAP30-like 0.021 1.4 Down
FGD4 FYVE, RhoGEF, and PH domain containing 4 0.026 1.52 Down
S100A2 S100 calcium-binding protein A2 0.005 1.53 Down
CTSZ Cathepsin Z 0.045 1.53 Down
SLC4A4 Solute carrier family 4, member 4 9.00E-04 1.54 Down
AGR3 Anterior gradient homolog 3 (Xenopus laevis) 0.011 1.69 Down
The table shows the list of underexpressed genes by 1.3-fold with a P value < 0.05 obtained in cells treated with caﬀeic acid and includes the gene symbol for
all genes, their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group and the type of
regulation (down: downregulation).
butein, the major biologically active polyphenolic compo-
nent of the stems of Rhus verniciflua, downregulated the
expression of STAT3-regulated gene products such as Bcl-xL,
Bcl-2, cyclin D1, and Mcl-1 [43].
STAT5B participates in diverse biological processes,
such as growth development, immunoregulation, apoptosis,
reproduction, prolactin pathway, and lipid metabolism.
STAT5B deficiency is a recently identified disease entity that
involves both severe growth hormone-resistant growth fail-
ure and severe immunodeficiency [44–46]. The induction of
STAT5B expression upon incubation with CA and ICC could
represent a nutritional tool to upregulate this transcription
factor and suggests novel research strategies for natural
therapies in Crohn’s disease and inflammatory bowel disease
in which STAT5B appears to maintain the mucosal barrier
integrity and tolerance [47, 48]. In colorectal cancer both
STAT5a and STAT5b play important roles in progression and
downregulation of both STAT5A and STAT5B results in a
gradual decrease in cell viability, predominantly attributed
to G1 cell cycle arrest, and apoptotic cell death [49]. In this
context the increase in STAT5B caused by ICC and CA would
have a negative eﬀect on colorectal cancer patients, as it
would trigger cell proliferation and survival.
In human breast cancer, STAT5A/B has been shown
a dual role in the mammary gland as an initiator of
tumor formation as well as a promoter of diﬀerentiation of
established tumors. STAT3, STAT5A, and STAT5B are over-
expressed or constitutively activated in breast cancer [50–
52] and active STAT5A/B in human breast cancer predicted
favorable clinical outcome [53]. Prolactin receptor signal
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Table 6: Common diﬀerentially expressed genes in HT29 treated-cells.
Gene symbol FC absolute ICC P value Regulation FC absolute CA P value Regulation
FST 1.343 0.025 Up 1.375 0.022 Up
SULT1B1 1.349 0.018 Up 1.304 0.020 Up
EPOR 1.372 0.008 Up 1.321 0.021 Up
HINT3 2.410 0.040 Up 2.607 0.033 Up
STAT5B 1.312 0.007 Up 1.334 0.012 Up
GLS 1.335 0.001 Down 1.370 0.001 Down
PPP3R1 1.397 0.023 Down 1.423 0.026 Down
ATF2 1.481 0.005 Down 1.354 0.016 Down
SLC4A7 1.314 0.029 Down 1.322 0.025 Down
MARCH3 1.330 0.016 Down 1.319 0.005 Down
TBL1XR1 1.426 0.001 Down 1.332 0.001 Down
SAP30L 1.375 0.013 Down 1.405 0.021 Down
FGD4 1.593 0.001 Down 1.523 0.027 Down
ZDHHC20 1.665 0.004 Down 1.314 0.005 Down
ZDHHC21 1.642 0.037 Down 1.318 0.016 Down
FAM76B 1.506 0.014 Down 1.325 0.037 Down
CLK4 1.326 0.049 Down 1.339 0.021 Down
Common diﬀerentially expressed genes in HT29 treated-cells with a P value < 0.05 and a minimum fold of 1.3. Column ICC correspond to cells treated with
instant caﬀeinated coﬀee and column CA corresponds to cells treated with caﬀeic acid. Overexpressed genes are indicated on the upper part of the table,
whereas underexpressed genes are depicted in the lower part. The genes in bold, STAT5B and ATF-2, were chosen for further analysis.
transduction through the Jak2-STAT5 pathway has been
considered to be essential for proliferation and diﬀerenti-
ation of normal mammary epithelial cells [54–56]. It has
been shown that the levels of NUC-pYSTAT5 decreased as
breast cancer progressed from normal to in situ, to invasive,
and then to nodal metastases [57]. Additionally Peck et al.
[57] found that the absence of detectable NUC-pYStat5 in
tumors of patients how where under antiestrogen therapy
was associated with poor breast cancer-specific survival. We
analyzed STAT5B modulation through the PRL pathway in
response to coﬀee polyphenols in a breast cancer cell line.
The MCF-7 cell line was chosen because expression of the
prolactin receptor is more often found in estrogen receptor-
positive breast tumors [58]. In our conditions, incubation
with CA and ICC led to an increase in STAT5B protein
levels in MCF-7 cells, and this result could be the basis for a
possible inclusion of coﬀee polyphenols in the diet of breast
cancer patients.
ATF-2 is a member of the ATF-cAMP response element-
binding protein (CREB) family of transcription factors that
can bind to the cAMP response element (CRE) found in
many mammalian gene promoters [59, 60]. ATF-2 exhibits
both oncogenic and tumor suppressor functions [61]. CREs
are found in several genes involved in the control of the
cell cycle, for example, the cyclin D1 gene, and ATF-2
binding to this sequence stimulates the transcription of
cyclin D1 [30, 31]. ATF-2 mediated cyclin D1 promoter
induction can be stimulated by a number of growth-
promoting agents, such as estrogen [31], hepatocyte growth
factor [62], and regenerating gene product [63]. ATF-2 has
been correlated with proliferation, invasion, migration, and
resistance to DNA-damaging agents in breast cancer cell
lines.
The downregulation of ATF-2 expression after CA and
ICC incubation in HT29 cells reported here is in accor-
dance with the observed decrease in activity of ATF-2 in
gastric cells when incubating with chlorogenic acid, the
precursor of caﬀeic acid [64]. Surprisingly, the validation
of the protein levels showed the upregulation of ATF-
2 protein with ICC, but not with CA, both in HT29
and MCF-7 cells. This diﬀerential behavior could be due
to other ICC components besides CA. In this direction
Rubach et al. [64] reported a diﬀerent response in ATF-2
activity after incubation of a gastric cell line with diﬀerent
coﬀee compounds. The presence of pyrogallol, catechol,
βN-alkanoylhydroxytryptamides, and N-methylpyridinium
increased ATF-2 activity, whereas chlorogenic acid and caf-
feine decrease it [64]. In our conditions incubation of HT29
cells with ICC caused a modest decrease in ATF-2 mRNA
levels. However this eﬀect was not translated at the protein
level. We hypothesize that ICC contains other polyphenols
in addition to caﬀeic acid that are able to increase ATF-
2 protein levels through an increase of the translation of
its mRNA, the increase of stability of the protein or an
inhibition of its degradation. In this direction several plant
polyphenols such as (-)-epigallocatechins-3-gallate (EGCG),
genistein, luteolin, apigenin, chrysin, quercetin, curcumin,
and tannic acid have been described to possess proteasome-
inhibitory activity [65, 66].
The regulation of ATF-2 transcriptional activity, mostly
at the level of its phosphorylation status, has been described
upon treatment of cancer cells with several natural com-
pounds. In MCF-7 cells, the anticancer agent 3,30-Diindo-
lylmethane, derived from Brassica vegetables, activates both
JNK and p38 pathways, resulting in c-Jun and ATF-2
phosphorylation, and the increase of binding of the
14 Oxidative Medicine and Cellular Longevity
c-Jun–ATF-2 homodimers and heterodimers to the proximal
regulatory element of IFN-γ promoter [67]. Biochanin-A,
an isoflavone, existing in red clover, cabbage and alfalfa, has
an inhibitory and apoptogenic eﬀect on certain cancer cells
by blocking the phosphorylation of p38 MAPK and ATF-2
in a dose-dependent fashion [68]. The JNK stress-activated
pathway is one of the major intracellular signal transduction
cascades involved in intestinal inflammation [69, 70], and
upregulation of ATF-2 has been shown in Crohn’s disease
[71, 72]. Thus CA could represent potential therapeutical
properties in diﬀerent states of intestinal inflammation due
to its combined eﬀects on STAT5B and ATF-2 in HT29 cells.
Finally, the modulation of cyclin D1, a target of STAT5B
and ATF-2 transcription factors, upon incubation with coﬀee
polyphenols was established in colon and breast cancer
cells. Cyclin D1 overexpression is common in colorectal
cancer, but the findings regarding its prognostic value are
conflicting. In a recent study, positive expression of cyclin D1
protein was detected in 95 of 169 colonic adenocarcinoma
specimens, and increased cyclin D1 levels were associated
with poorer prognosis [73]. Furthermore, there was a
significant correlation between the positive expression of p-
Stat5 and cyclin D1 in patients with colonic adenocarcinoma.
However, in a second study, cyclin D1 overexpression was
associated with improved outcome in a total of 386 patients
who underwent surgical resection for colon cancer, classified
as TNM stage II or III. Belt et al. [74] showed that low p21,
high p53, low cyclin D1, and high AURKA were associated
with disease recurrence in stage II and III colon cancer
patients. In this context the eﬀect of ICC on cyclin D1
levels could represent either a positive or a negative eﬀect
in colon cancer cells, depending on tumor progression. The
increase in cyclin D1 levels could represent a marker of
better outcome since it has been recently established that
cyclin D1 expression is strongly associated with prolonged
survival in male colorectal cancer and that lack of cyclin
D1 is associated with a more aggressive phenotype in male
patients [75]. However, several natural compounds such as
anthocyanins, anthocyanidins, apigenin, luteolin, and fisetin
have all been described to induce experimentally cell-cycle
arrest and apoptosis through the decrease of cyclin D1 levels
in HT29 cells [76–80]. In accordance to these data, the
increase observed in cyclin D1 levels in HT29 cells upon
incubation with ICC could probably be the consequence of
the presence of diﬀerent compounds other than polyphenols
in ICC.
In MCF-7 breast cancer cells, cyclin D1 was down-
regulated upon incubation with coﬀee polyphenols. The
rationale for the choice of MCF-7 cell line was based on
the observation that although cyclin D1 overexpression is
present across multiple histologic subtypes of breast cancer,
it has been shown that the large majority of cyclin D1–
overexpressing breast cancers are ER positive [24, 25, 81].
Cyclin D1 overexpression has been reported between 40
and 90% of cases of invasive breast cancer, while gene
amplification is seen in about 5–20% of tumors [24, 81–83].
In cyclin D1-driven cancers, blocking cyclin D1 expression
by targeting the cyclin D1 gene, RNA, or protein should
increase the chances for therapeutic success. Cell culture
studies have raised the possibility that certain compounds
might act in this way [84, 85] and approaches to blocking
cyclin D1 expression using antisense, siRNA, or related
molecules specifically target the driving molecular lesion
itself [86–88]. It is believed that compounds that modulate
cyclin D1 expression could have a role in the prevention and
treatment of human neoplasias. For instance, flavopiridol,
a synthetic flavonoid based on an extract from an Indian
plant for the potential treatment of cancer, induces a rapid
decline in cyclin D1 steady-state protein levels [89]. Taking
all these results together, inhibition of cyclin D1 expression
appears to be a good approach for cancer treatment. In this
direction our observation that coﬀee and caﬀeic acid are able
to drastically reduce the expression of cyclin D1 in breast
cancer cells could suggest that some coﬀee components could
be used as a coadjuvant therapeutic tool in the treatment of
breast cancer.
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